本综述旨在考察骨转移对免疫检查点抑制剂治疗的非小细胞肺癌（NSCLC）患者预后的影响。我们在PubMed、CENTRAL、Web of Science和Embase数据库中进行了文献搜索，截至2022年9月4日。通过随机效应模型对多变量调整后的数据进行了汇总。共纳入了13项研究。通过对10项研究进行合并分析，发现在使用ICIs治疗的NSCLC患者中，骨转移与较差的总生存期（OS）相关（HR: 1.55 95% CI 1.24, 1.94 I2 = 69% p = 0.001）。通过对7项研究进行荟萃分析，发现骨转移与NSCLC患者在使用ICIs治疗时的无进展生存期（PFS）无关（HR: 1.31 95% CI 0.85, 2.01 I2 = 85% p = 0.22）。使用年龄、男性性别、吸烟史、鳞状组织学和将ICIs作为一线治疗的中介变量进行荟萃回归分析，发现与OS的预后无统计学显著性。骨转移的存在是ICIs治疗的NSCLC患者预后较差的预测因素。然而，骨转移似乎不会影响PFS。临床医生应将骨转移的NSCLC患者管理置于优先位置，并探索使用联合治疗以取得最佳效果。进一步研究考虑到不同联合治疗方案将加强证据的支持。© 2023. 作者在Federación de Sociedades Españolas de Oncología（FESEO）独家授权下。

This review was implemented to examine the impact of bone metastasis on the prognosis of non-small cell lung cancer patients (NSCLC) treated with immune checkpoint inhibitors (ICIs).A literature search was conducted in the PubMed, CENTRAL, Web of Science, and Embase databases up to 4th September 2022. Multivariable adjusted data were pooled in a random-effects model.13 studies were included. On a combined analysis of 10 studies, it was noted that bony metastasis was associated with poor overall survival (OS) in NSCLC patients treated with ICIs (HR: 1.55 95% CI 1.24, 1.94 I2 = 69% p = 0.001). Meta-analysis of seven studies showed that bony metastasis was not associated with poor progression-free survival (PFS) in NSCLC patients treated with ICIs (HR: 1.31 95% CI 0.85, 2.01 I2 = 85% p = 0.22). Meta-regression analysis using the moderator's age, male gender, smoking history, squamous histology, and ICI as 1st line therapy for the outcome OS was not statistically significant.The presence of bone metastasis is a predictor of poor OS in NSCLC treated with ICIs. However, PFS does not seem to be influenced by the presence of bone metastasis. Clinicians should prioritize the management of NSCLC patients with bone metastasis and explore the use of combination therapies to achieve optimal results. Further studies taking into account different combination therapies for such patients would strengthen the evidence.© 2023. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).